Satellos advances forazapadin into FSHD clinical development

• Satellos Bioscience (NASDAQ:MSLE) received FDA clearance to begin a Phase 2 study of forazapadin in adults with facioscapulohumeral muscular dystrophy (FSHD).
• The randomized trial is expected to begin in Q4 2026 and will evaluate 60 mg and 120 mg doses of the oral drug candidate.
• FSHD Canada Foundation agreed to provide up to $5 million in milestone payments in exchange for a capped share of future FSHD-related proceeds.

Satellos Bioscience (NASDAQ:MSLE) announced that it has received U.S. Food and Drug Administration (FDA) clearance to begin studying forazapadin in patients with facioscapulohumeral muscular dystrophy (FSHD).

The clearance supports a planned Phase 2 clinical trial evaluating the oral drug candidate as a potential treatment for FSHD, a genetic muscle-wasting disorder.

The randomized, double-blind, placebo-controlled study is expected to begin in the fourth quarter of 2026 and will enroll adults aged 18 years and older.

The trial will evaluate the safety, tolerability, pharmacokinetics, and potential efficacy of two dose levels of forazapadin: 60 mg and 120 mg.

Satellos also announced a financing agreement with the FSHD Canada Foundation, under which the foundation will provide up to $5 million in milestone payments over the next five quarters.

In exchange, the foundation will receive a capped share of future proceeds related to FSHD applications of forazapadin.

Forazapadin is designed to target muscle regeneration pathways and is also being evaluated in Phase 2 clinical studies for Duchenne muscular dystrophy (DMD) in both pediatric and adult populations.

The FSHD study represents a second clinical indication for the drug candidate as Satellos continues to expand its muscular dystrophy development pipeline.